期刊
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
卷 14, 期 5, 页码 451-456出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ACI.0000000000000100
关键词
allergic conjunctivitis; rhinoconjunctivitis; sublingual immunotherapy
资金
- Ora, Inc
- Allergan, Inc (Irvine, USA)
- Alcon, Inc (Fort Worth, USA)
Purpose of review This review describes recent findings and trends in prevalence and treatment of allergic ocular diseases. Although the major focus is on seasonal and perennial allergic conjunctivitis, related disorders will also be considered. Recent findings Published reports from countries around the world suggest that the spectrum of atopic diseases, including seasonal and perennial allergic conjunctivitis, is continuing its pattern of increasing prevalence, which has been well documented over the past few decades. In addition, although treatment modalities have focused on topical formulations including antihistamines and corticosteroids, there is a significant emphasis on immunotherapy as an alternative treatment modality, particularly in the USA. Summary Allergic conjunctivitis is a key component in the spectrum of allergic diseases that is sometimes collectively referred to as rhinoconjunctivitis. Because of its high prevalence worldwide, it exacts an increasing toll in terms of patient discomfort, morbidity, and loss of productivity. Current estimates suggest that at least 20% of the overall population suffers from some form of allergic conjunctivitis, many without ever seeking treatments. In addition, a significant proportion of patients experience chronic forms of allergy that are less responsive to existing therapies. Recent approval of immunotherapy-based treatments may address this therapeutic gap.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据